This compound is primarily used in the field of cancer research and therapy, specifically targeting cancers associated with mutations in the IDH1 gene. It functions as an inhibitor of the mutant IDH1 enzyme, which is known to produce an oncometabolite, 2-hydroxyglutarate, that drives tumor growth. By inhibiting this enzyme, the compound helps to normalize cellular metabolism and reduce tumor progression. It is particularly relevant in the treatment of certain types of gliomas and acute myeloid leukemia (AML), where IDH1 mutations are prevalent. Research and clinical studies focus on its potential to improve patient outcomes by selectively targeting cancer cells while sparing healthy tissues.